Vanhee Celine, Deconinck Eric, George Mark, Hansen Andrew, Hackl Andreas, Wollein Uwe, El-Atma Oliver, Beerbaum Nico, Aureli Federica, Borioni Anna, Poplawska Magdalena, Blazewicz Agata, Roschel Karin, Marson Claude, Mendoza Barrios Magnolia, Hakkarainen Birgit, Blomgren Andreas, Bakker-'t Hart Ingrid, Miquel Marta
Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, J. Wytsmanstraat 14, 1050 Brussels, Belgium.
Therapeutic Goods Administration Laboratories, Australian Government Department of Health and Aged Care, P.O. Box 100, Woden, ACT 2606, Australia.
J Xenobiot. 2025 Jun 6;15(3):88. doi: 10.3390/jox15030088.
In recent years, an increasing number of case reports have mentioned the presence of illicit nootropics, smart drugs or mind doping products on the market. To better understand the extent of the problem, a market surveillance study was organised by the General European Official Medicines Control Laboratory Network and associated member Australia to detect substandard, falsified or illegal medicines or dietary supplements containing unauthorised nootropic molecules of natural or synthetic origin. From January 2020 to September 2024, 159 different samples were documented, which yielded a comprehensive dataset of 166 molecular identification entries. Within this dataset, 34 distinct molecules were identified. Most samples were sold or presented as dietary supplements (49%) or medicines (32%). The vast majority (69%) were collected from the illegal market. Prescription drugs and non-authorised drugs only available on prescription in Russia were found in pharmacological quantities; some of the latter (noopept, phenylpiracetam and phenibut) were intercepted as large bulk quantities of raw material. Unauthorised novel foods, prescription or higher amounts of melatonin, and clinically uncharacterised research molecules were also reported. This study highlights the need for more active monitoring and screening of such products, as consumption of some of the reported samples could have detrimental health effects. Furthermore, as a large number of the samples were presented as dietary supplements, consumers may not be aware of the possible dangers and side-effects of these products.
近年来,越来越多的病例报告提到市场上存在非法促智药、智能药物或精神刺激产品。为了更好地了解这一问题的严重程度,欧洲官方药品控制实验室总网络及相关成员澳大利亚组织了一项市场监测研究,以检测含有未经授权的天然或合成来源促智分子的不合格、伪造或非法药品或膳食补充剂。从2020年1月到2024年9月,记录了159个不同的样本,得到了一个包含166个分子识别条目的综合数据集。在这个数据集中,识别出了34种不同的分子。大多数样本作为膳食补充剂(49%)或药品(32%)出售或展示。绝大多数(69%)是从非法市场收集的。发现了处方药和仅在俄罗斯凭处方才能获得的未经授权的药物,且数量达到药理剂量;其中一些(诺吡酯、苯吡拉西坦和苯乙胺)被截获为大量原料。还报告了未经授权的新型食品、处方量或更高剂量的褪黑素以及临床上未明确特征的研究分子。这项研究强调了对此类产品进行更积极监测和筛查的必要性,因为食用一些报告的样本可能会对健康产生有害影响。此外,由于大量样本被作为膳食补充剂展示,消费者可能并未意识到这些产品可能存在的危险和副作用。